Find a Clinical Trial

Multimodality Treatment for Patients with Resectable Non-Small Cell Lung Cancer (BEACON Study: BEvacizumab And Chemotherapy for Operable NSCLC)

[Protocol 05-052]

---

Full Title :

MULTIMODALITY TREATMENT FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (BEACON STUDY: BEVACIZUMAB AND CHEMOTHERAPY FOR OPERABLE NSCLC)

Purpose :

The standard treatment for stage IB, II, and some stage IIIA non-small cell lung cancers is surgical removal of the tumor plus intravenous chemotherapy. Despite receiving both surgery and chemotherapy, however, some cancers are not cured.

Docetaxel and cisplatin are traditional chemotherapy drugs that have been shown to help some patients with non-small cell lung cancer. Bevacizumab (Avastin^TM) is a newer drug which has shown some benefit for patients with non-small cell lung cancer in clinical trials. It works by attaching to a protein in the blood stream called vascular endothelial growth factor, which helps tumors grow new blood vessels to feed themselves. Bevacizumab is thought to help block this new growth of blood vessels and starve the tumors of the nutrients they need.

The main purpose of this research is to evaluate the combination of bevacizumab, docetaxel, and cisplatin in patients with early-stage non-small cell lung cancer when given before surgery. A second goal is to assess the effectiveness of giving bevacizumab to patients for one year after their surgery.

In this study, some patients will receive all three drugs before surgery. Patients who have tumors with an increased risk of bleeding with bevacizumab will only receive docetaxel and cisplatin before surgery. In the second part of the study, all patients who have complete removal of their lung cancer at surgery will then receive bevacizumab every 3 weeks for one year.

Eligibility :

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

• Patients must have stage IB, II, or IIIA non-small cell lung cancer that can be surgically removed.
• Patients may not have had prior chemotherapy or radiation therapy for their lung cancer, nor any prior treatment with bevacizumab or similar drugs.
• Patients may not take blood-thinning drugs (such as warfarin, heparin, or daily anti-inflammatory drugs) during the trial.
• Patients must be age 18 or older.

For more information and to see if you are eligible for this study, please contact Dr. Naiyer Rizvi at 212-639-3204.